ReviewAmerican heart journal2020
Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock.
Registry-linked trialAbstract readReview
In one paragraph
Review in American heart journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06475456 (SPOKE-HUB SHOCK PROTOCOL MANAGEMENT ACCORDING TO SCAI CLASS IN TURIN AND MILAN AREA), which is not on this map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Spoke-hub shock protocol management according to scai class in turin and milan area
Who cites it
19 citing papers in PubMed.
- Impact of Baseline Cardiogenic Shock Severity on Outcomes in Patients Treated With Impella Device.Journal of the American Heart Association · 2025Observational
- The impact of cardiogenic shock and out-of-hospital cardiac arrest on the outcome of acute myocardial infarction: a national-level analysis.Internal and emergency medicine · 2025Article
- Article
- A Framework for Exception From Informed Consent in Trials Enrolling Patients With ST-Segment-Elevation Myocardial Infarction and Cardiogenic Shock.Journal of the American Heart Association · 2025Article
- Clinical Trials in Cardiogenic Shock: Challenges and Solutions for the Future.JACC. Advances · 2023Article
- Review
- Treatment Intensity for the Management of Cardiogenic Shock: Comparison Between STEMI and Non-STEMI.JACC. Advances · 2023Article
- Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come.European heart journal supplements : journal of the European Society of Cardiology · 2022Article
- Position Statement on Vascular Access Safety for Percutaneous Devices in AMI Complicated by Cardiogenic Shock.JACC. Cardiovascular interventions · 2022Review
- A Standardized and Regionalized Network of Care for Cardiogenic Shock.JACC. Heart failure · 2022Article
- Advocacy and Legislation for Regionalization Practices in the Treatment of Cardiogenic Shock: The Time Is Now.US cardiology · 2022Review
- Cardiogenic Shock Management and Research: Past, Present, and Future Outlook.US cardiology · 2022Review
- Review
- Cardiogenic Shock: Protocols, Teams, Centers, and Networks.US cardiology · 2021Review
- The Contemporary Cardiogenic Shock 'Playbook'.US cardiology · 2021Article
- Systems of Care in Cardiogenic Shock.Frontiers in cardiovascular medicine · 2021Review
- Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock.American heart journal · 2020Article
- Outcomes of Hospitalizations for Cardiogenic Shock at Left Ventricular Assist Device Versus Non-Left Ventricular Assist Device Centers.Journal of the American Heart Association · 2020Article
- A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock.JACC. Heart failure · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Marc SamskyDuke University Medical Center, Duke Clinical Research Institute, Durham Veterans Administration, Durham, NC. Electronic address: marc.samsky@duke.edu.
Mitchell KrucoffDuke University Medical Center, Cardiovascular Devices Unit, eECG Core Laboratories, Duke Clinical Research Institute, Durham, NC. Electronic address: mitchell.krucoff@duke.edu.
Andrew D AlthouseCenter for Research on Healthcare Data Center (CRHC-DC), Center for Clinical Trials & Data Coordination (CCDC), Division of General Internal Medicine, University of Pittsburgh School of Medicine, Circulation: Cardiovascular Interventions, Pittsburgh, PA. Electronic address: althousead@upmc.edu.
William T AbrahamDivision of Cardiovascular Medicine, The Ohio State University, Columbus, OH. Electronic address: william.abraham@osumc.edu.
Philip AdamsonAbbott, Austin, TX. Electronic address: Philip.adamson@abbott.com.
Fernando AguelOffice of Product Evaluation and Quality, CDRH | Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD. Electronic address: Fernando.Aguel@fda.hhs.gov.
Seth BilazarianAbiomed, Danvers, MA. Electronic address: sbilazarian@abiomed.com.
George D DangasMount Sinai Medical Center, New York, NY. Electronic address: George.Dangas@mountsinai.org.
Ian C GilchristPennsylvania State University, Heart and Vascular Institute, Hershey, PA. Electronic address: icg1@psu.edu.
Timothy D HenryThe Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, The Carl and Edyth Lindner Family Distinguished Chair in Clinical Research, The Christ Hospital Health Network, Cincinnati, OH. Electronic address: Tim.Henry@thechristhospital.com.
Judith S HochmanNYU-HHC Clinical and Translational Science Institute, New York University School of Medicine, NYU Langone Health, New York, NY. Electronic address: Judith.Hochman@nyulangone.org.
Navin K KapurThe CardioVascular Center, Tufts Medical Center Boston, MA. Electronic address: nkapur@tuftsmedicalcenter.org.
John LaschingerU.S. Food and Drug Administration, CDRH/OPEQ/Office of Clinical Evidence and Analysis (OCEA), 10903 New Hampshire Ave, Silver Spring, MD. Electronic address: john.laschinger@fda.hhs.gov.
Roy G MastersUniversity of Ottawa Heart Institute, Medical Adviser Health Canada, Ottawa, Ontario. Electronic address: roy.masters@canada.ca.
Eric MichelsonThomas Jefferson University, Philadelphia, PA. Electronic address: eric.michelsonmd@gmail.com.
David A MorrowCardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: DMORROW@BWH.HARVARD.EDU.
Valarie MorrowDuke Clinical Research Institute, Durham, NC. Electronic address: Valarie.morrow@duke.edu.
E Magnus OhmanDuke Program for Advanced Coronary Disease, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC. Electronic address: erik.ohman@duke.edu.
Ileana PinaWayne State University, Detroit, MI. Electronic address: Ileana.Pina@fda.hhs.gov.
Alastair G ProudfootDepartment of Perioperative Medicine, St. Bartholomew's Hospital, London. Electronic address: Alastair.Proudfoot@bartshealth.nhs.uk.
Joseph RogersDuke University Health System, Durham, NC. Electronic address: joseph.rogers@duke.edu.
John SapirsteinDivision of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Washington, DC.
Fred SenatoreDivision of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Washington, DC. Electronic address: Fortunato.Senatore@fda.hhs.gov.
Norman StockbridgeU.S. Food and Drug Administration, Center for Drug Evaluation and Research, 10903 New Hampshire Ave, Silver Spring, MD. Electronic address: norman.stockbridge@fda.hhs.gov.
Holger ThieleHeart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology Leipzig, Germany, Leipzig Heart Institute, Leipzig, Germany. Electronic address: Holger.Thiele@medizin.uni-leipzig.de.
Alexander G TruesdellVirginia Heart, INOVA Heart and Vascular Institute, Alexandria, VA. Electronic address: atruesdell@tcg.md.
Ron WaksmanSection of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC. Electronic address: Ron.waksman@medstar.net.
Sunil RaoDuke University Health System Section Chief, Cardiology, Durham VA Health System, Durham, NC. Electronic address: sunil.rao@duke.edu.
Funding
Postdoctoral Training in Cardiovascular Clinical ResearchT32HL069749 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2003 to 2023
$6.7MNHLBI NIH HHS T32 HL069749
Abstract
PubMed holds no abstract for this paper.
Indexed as
Advisory CommitteesConsensus Statements as TopicEvidence-Based MedicineRandomized Controlled Trials as TopicShock, CardiogenicAssisted CirculationBiomedical ResearchCardiac Care FacilitiesDevice ApprovalEmergenciesHemodynamicsHumansInformed ConsentPatient SelectionProbabilityProdromal Symptoms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06475456ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.